Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: Impact on survival

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Martínez, Ramón ^a,c   Stühmer, Walter ^b,c   Martin, Sabine ^b,c   Schell, Julian ^a,c   Reichmann, Andrea ^a,c   Rohde, Veit ^a,c   Pardo, Luis ^b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Brain metastases; Glioblastoma multiforme; Ion channel; Kv10.1; Potassium channel; Protein expression; Survival time; Tailored therapy; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; SERTRALINE; VOLTAGE GATED POTASSIUM CHANNEL; KCNH1 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CARCINOMA; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DEPRESSION; EAG1 GENE; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOGENESIS; PROSTATE CARCINOMA; AGED; BIOSYNTHESIS; BRAIN TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84946033543     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1848-y     Document Type: Article

References (46)

1. Martin S, De Oliveira CL, De Queiroz FM, Pardo LA, Stuhmer W, Del Bel E. Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neuroscience. 2008;155(3):833-44.
2. Ashcroft FM. From molecule to malady. Nature. 2006;440(7083):440-7.
3. Pardo LA, Bruggemann A, Camacho J, Stuhmer W. Cell cycle-related changes in the conducting properties of r-eag K+ channels. J Cell Biol. 1998;143(3):767-75.
4. + channels. EMBO J. 1999;18(20):5540-7.
5. Ousingsawat J, Spitzner M, Puntheeranurak S, Terracciano L, Tornillo L, Bubendorf L, et al. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res. 2007;13(3):824-31.
6. Farias LM, Ocana DB, Diaz L, Larrea F, Avila-Chavez E, Cadena A, et al. Ether a go-go potassium channels as human cervical cancer markers. Cancer Res. 2004;64(19):6996-7001.
7. Mello de Queiroz F, Suarez-Kurtz G, Stühmer W, Pardo LA. Ether a go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer. 2006;5:42.
8. Agarwal JR, Griesinger F, Stühmer W, Pardo LA. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer. 2010;9:18. doi: 10.1186/1476-4598-9-18.
9. Ding XW, Luo HS, Jin X, Yan JJ, Ai YW. Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med Oncol. 2007;24(3):345-50.
10. Ding XW, Wang XG, Luo HS, Tan SY, Gao S, Luo B, et al. Expression and Prognostic Roles of Eag1 in Resected Esophageal Squamous Cell Carcinomas. Dig Dis Sci. 2008;53(8):2039-44.
11. Menendez ST, Villaronga MA, Rodrigo JP, Alvarez-Teijeiro S, Garcia-Carracedo D, Urdinguio RG, et al. Frequent aberrant expression of the human ether à go-go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications. J Mol Med (Berl). 2012;90(10):1173-84.
12. Asher V, Khan R, Warren A, Shaw R, Schalkwyk GV, Bali A, et al. The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol. 2010;5:78. doi: 10.1186/1746-1596-5-78.
13. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66.
14. Ding XW, Yan JJ, An P, Lu P, Luo HS. Aberrant expression of ether a go-go potassium channel in colorectal cancer patients and cell lines. World J Gastroenterol. 2007;13(8):1257-61.
15. Pardo LA, Gomez-Varela D, Major F, Sansuk K, Leurs R, Downie BR, et al. Approaches targeting K(V)10.1 open a novel window for cancer diagnosis and therapy. Curr Med Chem. 2012;19(5):675-82.
16. Pardo LA, Stuhmer W. Eag1: an emerging oncological target. Cancer Res. 2008;68(6):1611-3.
17. Downie BR, Sánchez A, Knötgen H, Contreras-Jurado C, Gymnopoulos M, Weber C, et al. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J Biol Chem. 2008;283(52):36234-40.
18. + channel 1 (hEag1) regulates MDA-MB-231 breast cancer cell migration through Orai1-dependent calcium entry. J Cell Physiol. 2012;227(12):3837-46.
19. Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sánchez A, Hettmann T, Ossipov D, et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res. 2007;67(15):7343-9.
20. Weber C, de Queiroz FM, Downie BR, Suckow A, Sturhmer W, Pardo LA. Silencing the activity and proliferative properties of the human Eag1 potassium channel by RNA interference.(vol 281, pg 13030, 2006). J Biol Chem. 2006;281(25):17540-0.
21. Wu J, Wu X, Zhong D, Zhai W, Ding Z, Zhou Y. Short Hairpin RNA (shRNA) Ether a go-go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3K/AKT signaling. Int J Mol Sci. 2012;13(10):12573-83.
22. Gavrilova-Ruch O, Schönherr K, Gessner G, Schönherr R, Klapperstuck T, Wohlrab W, et al. Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol. 2002;188(2):137-49.
23. + channel. Recept Channels. 2001;7(5):345-56.
24. Patt S, Preussat K, Beetz C, Kraft R, Schrey M, Kalff R, et al. Expression of ether a go-go potassium channels in human gliomas. Neurosci Lett. 2004;368(3):249-53.
25. + Channels by Imipramine and Astemizole. J Gen Physiol. 2004;124(4):301-17.
26. Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L, et al. MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer. 2013;49(3):710-24.
27. Hemmerlein B, Weseloh RM, de Queiroz FM, Knötgen H, Sánchez A, Rubio ME, et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer. 2006;5:41.
28. Cunha LC, Del Bel E, Pardo L, Stuhmer W, Titze-DE-Almeida R. RNA interference with EAG1 enhances interferon gamma injury to glioma cells in vitro. Anticancer Res. 2013;33(3):865-70.
29. Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro-Oncology. 2012;14(9):1171-7.
30. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-51.
31. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database. Int J Radiat Oncol Biol Phys. 2008;70(2):510-4.
32. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents. New Engl J Med. 2000;343(19):1350-4.
33. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New Engl J Med. 2005;352(10):997-1003.
34. + channel. PloS one. 2011;6(5), e20362.
35. Daley E, Wilkie D, Loesch A, Hargreaves IP, Kendall DA, Pilkington GJ, et al. Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun. 2005;328(2):623-32.
36. Xia Z, Bergstrand A, DePierre JW, Nassberger L. The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47.
37. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci. 2005;27(1):29-42.
38. Merry S, Hamilton TG, Flanigan P, Freshney RI, Kaye SB. Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur J Cancer. 1991;27(1):31-4.
39. Pommerenke EW, Volm M. Reversal of doxorubicin-resistance in solid tumors by clomipramine. In Vivo. 1995;9(2):99-101.
40. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 2013;3(12):1364-77.
41. Ma J, Hou LN, Rong ZX, Liang P, Fang C, Li HF, et al. Antidepressant desipramine leads to C6 glioma cell autophagy: implication for the adjuvant therapy of cancer. Anticancer Agents Med Chem. 2013;13(2):254-60.
42. Jeon SH, Kim SH, Kim Y, Kim YS, Lim Y, Lee YH, et al. The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. Biochem Biophys Res Commun. 2011;413(2):311-7.
43. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIF-alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-8.
44. Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013;24(3):379-93.
45. Dumitru CA, Sandalcioglu IE, Wagner M, Weller M, Gulbins E. Lysosomal ceramide mediates gemcitabine-induced death of glioma cells. J Mol Med. 2009;87:1123-32.
46. Gramatzki D, Herrmann C, Happold C, Becker KA, Gulbins E, Weller M, et al. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS One. 2013;8(5), e63527. doi: 10.1371/journal.pone.0063527.